Stockreport

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist, in post-bariatric hypoglycemia underway; completion of recruitment exp [Read more]